Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One prick, three diseases: new rapid test under study

NCT ID NCT06082336

Diagnosis Sponsor: MagIA Diagnostics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study is testing a new medical device called MagIA IBC that uses a single drop of blood from a finger prick to screen for HIV, hepatitis B, and hepatitis C at the same time. Researchers will enroll 252 adults who are known or suspected to have one of these infections. The goal is to see how accurate the test is compared to standard lab tests, and whether it works reliably with different types of blood samples.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MagIA IBC diagnostic test
What this could lead to
If successful, this could provide a quick, single finger-prick test to screen for HIV, hepatitis B, and hepatitis C, making diagnosis faster and more accessible.
What could go wrong
This is an early-stage study with only 252 participants, so results may not apply to everyone. The test's accuracy is still being evaluated, and it may not perform as well in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

96 people

The number who actually took part.

Started

Sep 2024

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: IC1. A Male or Female aged of at least 18 years IC2. A person responding to one of the following conditions: * known having HIV infection * or known having HBV infection * or known or suspected having HCV infection with anti-HCV RDT positive. IC3. A person having given consent to participate the study, IC4. A person covered by a medical insurance or being enrolled during an outdoor testing campaign. Exclusion Criteria: EC1. A person for whom blood sampling would represent a risk, EC2. A person protected by law (minor, under guardianship or curatorship, childbearing, or breastfeeding female, hospitalized without consent, under administrative or judicial supervision)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Combined point of care diagnostic of HIV, HBV and HCV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection hepatitis C virus infection HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Combined point of care diagnostic of HIV, HBV and HCV

Contacts and locations

Locations

  • Centre Hospitalier de Perpignan - Equipe Mobile Hépatites

    Perpignan, 66000, France

  • Hopital Européen de Marseille

    Marseille, France, 13003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.